Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
Diverse malignancies either associated with or thought to be associated with activated
tyrosine kinase enzymes including hypereosinophilic syndrome systemic mastocytosis chronic
myelomonocytic leukaemia, dermatofibrosarcoma protuberans and other diseases.
Patients with chronic myeloid leukemia, some other types of leukemias (abl-mutated) some
types of gastrointestinal stromal tumours (c-KIT-positive), some systemic mastocytosis (if
c-KIT D816V mutation), brain, prostate, breast or lung cancers.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
To assess the efficacy and the safety of imatinib mesylate therapy
Australia: Department of Health and Ageing Therapeutic Goods Administration